GLCCI1-DT

Across TCGA pan-cancer cohorts, GLCCI1-DT RNA differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of GLCCI1-DT’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where GLCCI1-DT RNA is repressed in tumor relative to normal tissue. In most cancer types GLCCI1-DT is over-expressed in tumor, although a few such as THCA and LUSC show the opposite, repressed pattern.

THCA, LUSC, and KIRC are the cancer types where GLCCI1-DT tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in GLCCI1-DT RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	Male	III,IV	−0.891	<.001	11	view →
LUSC	All	All	−0.288	<.001	7	view →
KIRC	Female	All	−0.157	.003	6	view →
BLCA	All	IV	+0.325	.043	3	view →
KIRP	All	All	−0.154	.001	3	view →
HNSC	All	III,IV	+0.102	.028	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

GLCCI1-DT–THCA

Open the THCA breakdown →